Literature DB >> 30413672

Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8+ T Cells.

Alba Grifoni1, Priscilla Costa-Ramos2, John Pham1, Yuan Tian1, Sandy L Rosales1, Grégory Seumois1, John Sidney1, Aruna D de Silva1,3, Lakshmanane Premkumar4, Matthew H Collins4,5, Mars Stone6, Phillip J Norris6, Claudia M E Romero7, Anna Durbin8, Michael J Ricciardi9, Julie E Ledgerwood10, Aravinda M de Silva4, Michael Busch6, Bjoern Peters1,11, Pandurangan Vijayanand1, Eva Harris12, Andrew K Falconar7, Esper Kallas2, Daniela Weiskopf1, Alessandro Sette13,11.   

Abstract

Zika virus (ZIKV) constitutes an increasing public health problem. Previous studies have shown that CD8+ T cells play an important role in ZIKV-specific protective immunity. We have previously defined antigenic targets of the ZIKV-specific CD8+ T cell response in humans. In this study, we characterized the quality and phenotypes of these responses by a combined use of flow cytometry and transcriptomic methods, using PBMCs from donors deriving from different geographical locations collected in the convalescent phase of infection. We show that ZIKV-specific CD8+ T cells are characterized by a polyfunctional IFN-γ signature with upregulation of TNF-α, TNF receptors, and related activation markers, such as CD69, as well as a cytotoxic signature characterized by strong upregulation of GZMB and CRTAM. The signature is stable and not influenced by previous dengue virus exposure, geographical location, or time of sample collection postinfection. To our knowledge, this work elucidates the first in-depth characterization of human CD8+ T cells responding to ZIKV infection.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30413672      PMCID: PMC6287102          DOI: 10.4049/jimmunol.1801090

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells.

Authors:  Daniela Weiskopf; Michael A Angelo; Elzinandes L de Azeredo; John Sidney; Jason A Greenbaum; Anira N Fernando; Anne Broadwater; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Kimberly A Mattia; Benjamin J Doranz; Howard M Grey; Sujan Shresta; Bjoern Peters; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-11       Impact factor: 11.205

2.  TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates.

Authors:  Sinu Paul; John Sidney; Alessandro Sette; Bjoern Peters
Journal:  Curr Protoc Immunol       Date:  2016-08-01

3.  CC chemokine ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following viral infection.

Authors:  Matthew J Trifilo; Cornelia C Bergmann; William A Kuziel; Thomas E Lane
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Atypical IκB proteins - nuclear modulators of NF-κB signaling.

Authors:  Marc Schuster; Michaela Annemann; Carlos Plaza-Sirvent; Ingo Schmitz
Journal:  Cell Commun Signal       Date:  2013-04-11       Impact factor: 5.712

5.  CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals.

Authors:  Mayumi Yoshimori; Ken-Ichi Imadome; Honami Komatsu; Ludan Wang; Yasunori Saitoh; Shoji Yamaoka; Tetsuya Fukuda; Morito Kurata; Takatoshi Koyama; Norio Shimizu; Shigeyoshi Fujiwara; Osamu Miura; Ayako Arai
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

6.  Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge.

Authors:  Jinsheng Wen; Annie Elong Ngono; Jose Angel Regla-Nava; Kenneth Kim; Matthew J Gorman; Michael S Diamond; Sujan Shresta
Journal:  Nat Commun       Date:  2017-11-13       Impact factor: 14.919

7.  Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation.

Authors:  Tizong Miao; Alistair L J Symonds; Randeep Singh; Janine D Symonds; Ane Ogbe; Becky Omodho; Bo Zhu; Suling Li; Ping Wang
Journal:  J Exp Med       Date:  2017-05-09       Impact factor: 14.307

8.  Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection.

Authors:  Matthew H Collins; Eileen McGowan; Ramesh Jadi; Ellen Young; Cesar A Lopez; Ralph S Baric; Helen M Lazear; Aravinda M de Silva
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

9.  Severe dengue epidemics in Sri Lanka, 2003-2006.

Authors:  Nalaka Kanakaratne; Wahala M P B Wahala; William B Messer; Hasitha A Tissera; Aruna Shahani; Nihal Abeysinghe; Aravinda M de-Silva; Maya Gunasekera
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

10.  Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses.

Authors:  Jesse J Waggoner; Lionel Gresh; Alisha Mohamed-Hadley; Gabriela Ballesteros; Maria Jose Vargas Davila; Yolanda Tellez; Malaya K Sahoo; Angel Balmaseda; Eva Harris; Benjamin A Pinsky
Journal:  Emerg Infect Dis       Date:  2016-07-15       Impact factor: 6.883

View more
  30 in total

1.  Candidate Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology- and Bioinformatic-Based Predictions.

Authors:  Alba Grifoni; John Sidney; Yun Zhang; Richard H Scheuermann; Bjoern Peters; Alessandro Sette
Journal:  SSRN       Date:  2020-02-25

Review 2.  Transcriptomic immune profiles of human flavivirus-specific T-cell responses.

Authors:  Alba Grifoni; Yuan Tian; Alessandro Sette; Daniela Weiskopf
Journal:  Immunology       Date:  2020-01-07       Impact factor: 7.397

Review 3.  Epitope prediction and identification- adaptive T cell responses in humans.

Authors:  John Sidney; Bjoern Peters; Alessandro Sette
Journal:  Semin Immunol       Date:  2020-10-31       Impact factor: 11.130

4.  Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.

Authors:  Danielle Thompson; Ben Guenther; Darly Manayani; Jason Mendy; Jonathan Smith; Diego A Espinosa; Eva Harris; Jeff Alexander; Lo Vang; Christopher S Morello
Journal:  PLoS Negl Trop Dis       Date:  2022-07-06

Review 5.  Protective and enhancing interactions among dengue viruses 1-4 and Zika virus.

Authors:  Leah C Katzelnick; Sandra Bos; Eva Harris
Journal:  Curr Opin Virol       Date:  2020-09-24       Impact factor: 7.090

Review 6.  Protection against dengue virus requires a sustained balance of antibody and T cell responses.

Authors:  Kristen M Valentine; Michael Croft; Sujan Shresta
Journal:  Curr Opin Virol       Date:  2020-08-13       Impact factor: 7.090

Review 7.  The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development.

Authors:  Alyssa Fatic; Nan Zhang; Michael D Keller; Patrick J Hanley
Journal:  Transfusion       Date:  2019-08-30       Impact factor: 3.337

8.  Zika virus infection during pregnancy protects against secondary infection in the absence of CD8+ cells.

Authors:  Blake Schouest; Brandon J Beddingfield; Margaret H Gilbert; Rudolf P Bohm; Faith Schiro; Pyone P Aye; Antonito T Panganiban; Diogo M Magnani; Nicholas J Maness
Journal:  Virology       Date:  2021-04-09       Impact factor: 3.616

9.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2.

Authors:  Alba Grifoni; John Sidney; Yun Zhang; Richard H Scheuermann; Bjoern Peters; Alessandro Sette
Journal:  Cell Host Microbe       Date:  2020-03-16       Impact factor: 21.023

10.  Time elapsed between Zika and dengue virus infections affects antibody and T cell responses.

Authors:  Erick X Pérez-Guzmán; Petraleigh Pantoja; Crisanta Serrano-Collazo; Mariah A Hassert; Alexandra Ortiz-Rosa; Idia V Rodríguez; Luis Giavedoni; Vida Hodara; Laura Parodi; Lorna Cruz; Teresa Arana; Laura J White; Melween I Martínez; Daniela Weiskopf; James D Brien; Aravinda de Silva; Amelia K Pinto; Carlos A Sariol
Journal:  Nat Commun       Date:  2019-09-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.